PureTech Health ADR Representing 10 Ord Shs PRTC

Healthcare Biotechnology

PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.

NDAQ:PRTC - Post by User

PureTech Health ADR Representing 10 Ord Shs

<< Previous

Bullboard Posts

Post by whytestockson Oct 21, 2024 2:47am

44 Views

Post# 36274191

PureTech Founded Entity Seaport Therapeutics Closes $225 Mil

Just In: $PRTC PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing RoundFinancing led by General Atlantic with participation from other top tier investors Proceeds will support key clinical milestones in Seaport’s pipeline of first and best-in-class neuropsychiatric medicines PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or ...PRTC - PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

<< Previous

Bullboard Posts

Rig Count Soars as Utilization Surpasses Industry Averages